Literature DB >> 41684

The significance of 2,3-DPG in red blood cell transfusions.

P R Sohmer, R B Dawson.   

Abstract

This review will begin by giving the highlights of the history and explain development of the basic science knowledge of hemoglobin chemistry, function, and physiology. The necessary involvement of red cell metabolism, as it pertains to the maintenance of 2,3-diphosphoglycerate (2,3-DPG) levels, both normally and under the perturbed and experimental conditions of blood storage, will be given as part of the basic science data. The clinical science and transfusion data will comprise the main critical aspects of the paper. Analysis and comment of over 20 studies will be given on the effects of animal and human transfusions with altered 2,3-DPG levels. Decreased survival and organ function have been demonstrated with transfusion of low 2,3-DPG red cells, with or without anemia, in the conditions of exercise, shock, hypotension, ischemia, cardiac surgery, hypoxia, sepsis, and acidosis. By critical analysis of these studies, recommendations on general and specific patient needs for red cell transfusions with normal or high 2,3-DPG levels are given.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41684     DOI: 10.3109/10408367909105855

Source DB:  PubMed          Journal:  CRC Crit Rev Clin Lab Sci        ISSN: 0590-8191


  3 in total

1.  Brain O2 reserve in sickle cell disease.

Authors:  John C Wood
Journal:  Blood       Date:  2019-05-30       Impact factor: 22.113

2.  Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias.

Authors:  Chau Vu; Adam Bush; Soyoung Choi; Matthew Borzage; Xin Miao; Aart J Nederveen; Thomas D Coates; John C Wood
Journal:  Am J Hematol       Date:  2021-05-12       Impact factor: 13.265

3.  Transfusion of red blood cells stored for shorter versus longer duration for all conditions.

Authors:  Akshay Shah; Susan J Brunskill; Michael Jr Desborough; Carolyn Doree; Marialena Trivella; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2018-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.